Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 18 years of age
- People who have been diagnosed with heart failure that has been rated as moderate to severe in terms of how it affects daily activity (graded II–IV on a standard heart function scale)
- People who are already taking standard heart failure medications as recommended by current medical guidelines, which may include medicines that relax blood vessels (ACE inhibitors, ARBs, or a combined replacement for these), heart-rate and blood pressure medicines (beta blockers), medicines that help the heart manage fluid and salt balance (mineralocorticoid receptor antagonists), and water tablets (diuretics) if needed
- People who have read and signed a consent form agreeing to take part in the trial
Who may not be able to join:
- People who have an acute (sudden or severe) heart or blood vessel illness, or a serious widespread infection, that may be causing heart problems rather than heart failure itself
- People who have certain other heart conditions, such as serious heart defects present from birth, inflammation of the heart muscle, or significant problems with the heart valves
- People who are currently pregnant or breastfeeding
- People who have a cancerous tumour, an overactive thyroid gland, failure of multiple organs, or severely reduced kidney function (confirm with trial site for exact kidney function threshold)
- People who have difficulty communicating verbally or who have significant cognitive or psychological impairment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nada Nabil Mohammed Elsalhey, Bsc, clinical pharmacy department, kafrelsheikh university
Phone: +201062787805
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
measure effect of SGLT2I ON serum concentration ( level) of cardiac biomarkers in heart failure patients before and after the intervention; clinical examination for the presence and extent of improvement in signs and symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.